The risk of kidney dysfunction in metabolically healthy/unhealthy population with normal weight or overweight/obesity: a systematic review and meta-analysis Authors: Majid Valizadeh, Amirhossein Ramezani Ahmadi, Faeze Abbaspour, Ali Valizadeh, Ahad Hasan Syed Hasani, Seyed Mohammadmisagh Moteshakereh, Mohammad Nikoohemmat, Behnaz Abiri Published: 2024 ABSTRACT BackgroundChronic kidney disease (CKD) is a major global health concern with increasing prevalence and associated complications. Obesity and obesity-related metabolic disorders have been linked to chronic kidney disease (CKD), although the evidence is still inconsistent. To investigate the relationship between different obesity phenotypes and the risk of CKD, we conducted a systematic review and meta-analysis.MethodWe conducted a comprehensive search of databases for all relevant studies up to February 2024, without imposing a specific start date, for observational studies assessing the relationship between obesity phenotypes and incident kidney dysfunction. We used fixed and random effects models for the meta-analysis, subgroup analyses were carried out to explore heterogeneity, and Egger’s and Begg’s tests were used to assess publication bias.ResultThis meta-analysis included 13 eligible observational studies with 492,829 participants. Pooling the studies regardless of the effect measure showed that individuals with metabolically unhealthy normal weight (MUNW) (ES = 1.58, 95% CI = 1.43–1.76), metabolically healthy obese (MHO) (ES = 1.20, 95% CI = 1.06–1.34), and metabolically unhealthy obese (MUO) (ES = 1.90, 95% CI = 1.63–2.20) phenotypes had a significantly increased risk for kidney dysfunction (KD) events. On the other hand, MUOW individuals did not significantly correlate with risk of CKD (ES = 1.63, 95% CI = 0.97–2.23) compared to the MHNW phenotype.ConclusionHealthy overweight and obese individuals had higher risk for the incident KD events; refuting the notion that metabolically healthy overweight and obese phenotypes are benign conditions.Level of evidence: III Evidence obtained from well-designed cohort or cross-sectional studies.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40519-024-01697-x. Introduction Globally, chronic kidney disease (CKD) is a significant clinical and public health issue [1]. Chronic kidney disease is a significant risk factor not only for end-stage renal disease (ESRD), but also for cardiovascular disease [2] and higher death rates [3]. Because there is no effective therapy for ESRD, identifying the early risk factors for CKD is crucial [4]. One of the major risk factors for CKD is obesity [5] and obesity-related metabolic disorders such as diabetes, hypertension, and metabolic syndrome [6]. However, there is disagreement regarding the contribution of obesity to renal insufficiency [7], and it remains unclear whether metabolic abnormalities associated with obesity precede obesity itself. The majority of studies indicate that the glomerular filtration rate (GFR) is decreased in obese individuals [8, 9], although not all studies support this finding [10, 11]. There is a possibility that these discrepancies due to the heterogeneity of obesity phenotypes [12]. In fact, much of the increased risk for CKD among individuals with obesity is thought to stem from underlying cardiometabolic abnormalities associated with excess adiposity [13]. Nevertheless, not every obese individual will experience the metabolic problems associated with obesity. The variability in obesity outcomes is produced when obesity is combined with distinct metabolic characteristics. Consequently, six subtypes of the population can be identified: metabolically healthy with normal weight (MHNW), metabolically healthy overweight (MHOW), metabolically healthy obese (MHO), metabolically unhealthy with normal weight (MUNW), metabolically unhealthy overweight (MUOW), and metabolically unhealthy obese (MUO) [14]. Currently, various studies yielded contradictory effects of obesity-metabolic subphenotypes on the risk of developing CKD. Additionally, data from these isolated investigations might not provide sufficient evidence to support a potential differential risk for CKD. Therefore, it is essential to synthesize the findings of these related investigations. Here, we conducted a systematic review and meta-analysis of observational studies to determine the associations of different obesity phenotypes with the risk of CKD. Methods Search strategy We conducted a systematic review of observational studies examining the associations between various obesity phenotypes and the risk of chronic kidney disease (CKD). Our literature search was exhaustive, covering databases such as PubMed, Scopus, EMBASE, Web of Science, and Google Scholar up to February 2024, without restrictions on date or language. Additionally, we performed an in-depth bibliographic analysis of relevant publications to identify further studies. The search terms utilized included “kidney failure”, “chronic renal insufficiency”, “chronic kidney disease”, “CKD”, “chronic renal disease”, “obesity”, “body mass index”, “overweight”, “normal weight”, “metabolically healthy”, and “metabolically unhealthy” (see Supplementary 1). Only articles published in English were included in the final selection. The study selection process is illustrated in Fig. 1. The systematic review was in line with the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement [15]. Pre-registration code of the systematic review and meta-analysis protocols in PROSPERO is 564,164.Fig. 1PRISMA flow diagram for selection process of the studies PRISMA flow diagram for selection process of the studies Eligibility criteria Studies were considered suitable for meta-analysis if they met the following criteria: (1) utilized a cross-sectional or cohort design; (2) examined participants with both metabolically healthy and unhealthy obesity phenotypes, with kidney dysfunction as the outcome; (3) categorized subjects based on body mass index (BMI); (4) provided hazard ratios (HRs) or odds ratios (ORs) for kidney dysfunction incidents; and (5) disclosed the criteria for categorizing subjects as metabolically healthy or unhealthy. Clinical trials, literature reviews, animal studies, genetic research, and studies that did not report renal dysfunction occurrences in the subgroups were excluded from evaluation. Study selection After removing duplicates, two authors (BA and FA) independently evaluated the titles and abstracts obtained from the initial search. Both authors (BA and FA) assessed the full-text articles to ensure they met the eligible inclusion and exclusion criteria. Any disagreements were reevaluated by a third author (ARA). Data extraction and quality assessment We extracted information about the first author, year of publication, country, study design, population, the number and age of participants, follow-up duration, definitions of obesity phenotypes, definition of kidney dysfunction, and confounding factors that were adjusted for the analysis. Only the fully adjusted effect estimates reported in the studies were extracted and subsequently included in the meta-analysis. In this systematic review and meta-analysis, the quality of nonrandomized studies was assessed using the Newcastle–Ottawa Scale (NOS) [16]. The NOS evaluates studies based on eight items divided into three categories: selection, comparability, and exposure. Each item offers several response options, with the highest quality studies receiving a maximum of one star per item. An exception is made for the comparability category, where up to two stars can be awarded. Consequently, the NOS operates as a nine-star rating system [17]. Table 1 details the quality assessment and data extraction processes utilized in this study.Table 1Characteristics of the studies included in the meta-analysisFirst author [reference no.]CountryStudy designFollow-up duration (year)Number of participants (F/M)PopulationAgeDefinition of obesity phenotypeDefinition of KD and/or albuminuria/proteinuriaAdjustmentsNOSJam [18]IranCross-sectionalNA9762 (5061/4701)Participants from the baseline phase of the RaNCD study47.33 ± 8.27BMI was employed to identify obesity. Metabolic health was determined according to the IDF criteriaGFR < 60Age, smoke, alcohol, physical activity, SES, CVD, GGT, ALT, AST, Sodium intake6Adair [19]USACross-sectionalNA9599 (6108/3491)Patients from a large FQHC53.53 (14.32)Obesity was defined as BMI > 30 kg/m2. Metabolic health was classified as the absence of metabolic abnormalities defined by the NCEP ATP III criteria, excluding WCGFR < 60Sex, age, smoke7Cho [20]KoreaRetrospective cohort4319,674 (146,847/172827)Participants from the NHIS-HEALS40–79Obesity was defined based on the BMI criteria and WC. Metabolic health was defined according to the ATP III criteriaGFR < 60Age, sex, smoke, alcohol, physical activity, LDL, GFR7Chen [21]TaiwanCross-sectionalNA14,983 (5626/9357)General population49.4 ± 12.5Obesity was defined based on the BMI. Metabolic health was defined according to the ATP III criteriaGFR < 60 or proteinuriaSex, age, smoke, alcohol, ALT, CRP8Yang [22]KoreaRetrospective cohort148865 (4269/4596)Participants from the KoGESAdulthoodObesity was defined based on the BMI. Metabolic health was defined according to the ATP III criteriaGFR < 60Sex, age, smoke, alcohol, income, GFR, physical activity, CVD, ALT, AST, Uric Acid, CRP, GTP6Echouffo-Tcheugui [23]USAProspective cohort144291 (2236/2055)Participants from Framingham Offspring StudyMean age: 44.7Obesity was defined based on the BMI. Metabolic health was defined according to the NCEP ATP III criteriaGFR < 60 or microalbuminuriaAge, sex, smoke6Nam [24]KoreaProspective cohort9.58589 (4479/4110)Participants from the KoGES51.9 ± 8.8Obesity was defined based on the BMI. Metabolic health was defined according to the ATP III criteriaGFR < 60Age, smoke, alcohol, physical activity, CVD, residence7Lin [25]ChinaProspective cohort3.92491 (1515/976)General population59.5 ± 9.1Obesity was defined based on the BMI. Metabolic health was defined according to the ATP III criteriaGFR < 60 or Albuminuria (UACR ≥ 30 mg/g)Sex, age, smoke, alcohol, GFR, physical activity, ALT, CRP, GGT, uric acid, HOMA-IR, CVD, education, occupation5Chang [26]KoreaProspective cohort1062,249 (30,812/31437)Participants from the Kangbuk Samsung Health Study36.1 ± 6.6Obesity was defined based on the BMI. Metabolic health was defined as a HOMA-IR < 2.5 and absence of any component of the metabolic syndromeGFR < 60Sex, age, smoke, alcohol, GFR, physical activity, ALT, CRP, GGT, LDL, HDL, TG, FBS, HOMA-IR, AST, SBP, study center, year of screening8Jung [27]KoreaProspective cohort3.241,194 (16,275/24919)Subjects who visited the Health Screening and Promotion Center of Asan Medical Center for routine medical examinations>20Obesity was defined based on the Asia–Pacific BMI criteria. Metabolic health was defined according to the ATP III criteriaGFR < 60Sex, age, smoke, alcohol, GFR, physical activity, CVD, ALT, uric acid, CRP, GGT, LDL8Mottaghi [28]IranProspective cohort8.15672 (3108/2564)Participants from the Tehran Lipid and Glucose Study40.4 ± 0.2Obesity was defined based on the BMI. Metabolic health was defined according to the NCEP ATP III criteriaStructural or functional abnormalities of kidney for at least 3 months, manifested by either kidney damage with or without GFR < 60 or a decreased GFR with or without other evidence of kidney damageSex, age, smoke, HTN, WC6Hashimoto [29]JapanRetrospective cohort83136 (1303/1833)Participants from the Oike Health SurveyAdult populationObesity was defined based on the BMI. Metabolic health was defined according to the IDF criteriaGFR < 60 or proteinuriaSex, age, smoke, alcohol, Cr, uric acid, SBP, HDL, IFG5Chen [30]ChinaCross-sectionalNA2324 (1568/756)General population≥18Obesity was defined based on the BMI. Metabolic health was defined according to the IDF criteriaGFR < 60 or albumin-to-creatinine ratio (ACR) ≥ 30Sex, age, smoke, alcohol, physical activity, education, traditional Chinese medicine, CRP5F female, M male, GFR glomerular filtration rate, IDF International Diabetes Federation, NA not applicable, SES socio-economic status, CVD cardiovascular disease, GGT γ-glutamyltransferase, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, NCEP ATP III National Cholesterol Education Program Adult Treatment Panel III, WC waist circumference, CRP C-reactive protein, FBS fasting blood sugar, HOMA-IR homeostasis model assessment of insulin resistance, SBP systolic blood pressure, IFG impaired fasting glucose, NOS Newcastle–Ottawa Scale, ACR albumin-to-creatinine ratio, KD kidney disease, Cr creatinine, HTN hypertension, LDL low-density lipoprotein Table 1Characteristics of the studies included in the meta-analysisFirst author [reference no.]CountryStudy designFollow-up duration (year)Number of participants (F/M)PopulationAgeDefinition of obesity phenotypeDefinition of KD and/or albuminuria/proteinuriaAdjustmentsNOSJam [18]IranCross-sectionalNA9762 (5061/4701)Participants from the baseline phase of the RaNCD study47.33 ± 8.27BMI was employed to identify obesity. Metabolic health was determined according to the IDF criteriaGFR < 60Age, smoke, alcohol, physical activity, SES, CVD, GGT, ALT, AST, Sodium intake6Adair [19]USACross-sectionalNA9599 (6108/3491)Patients from a large FQHC53.53 (14.32)Obesity was defined as BMI > 30 kg/m2. Metabolic health was classified as the absence of metabolic abnormalities defined by the NCEP ATP III criteria, excluding WCGFR < 60Sex, age, smoke7Cho [20]KoreaRetrospective cohort4319,674 (146,847/172827)Participants from the NHIS-HEALS40–79Obesity was defined based on the BMI criteria and WC. Metabolic health was defined according to the ATP III criteriaGFR < 60Age, sex, smoke, alcohol, physical activity, LDL, GFR7Chen [21]TaiwanCross-sectionalNA14,983 (5626/9357)General population49.4 ± 12.5Obesity was defined based on the BMI. Metabolic health was defined according to the ATP III criteriaGFR < 60 or proteinuriaSex, age, smoke, alcohol, ALT, CRP8Yang [22]KoreaRetrospective cohort148865 (4269/4596)Participants from the KoGESAdulthoodObesity was defined based on the BMI. Metabolic health was defined according to the ATP III criteriaGFR < 60Sex, age, smoke, alcohol, income, GFR, physical activity, CVD, ALT, AST, Uric Acid, CRP, GTP6Echouffo-Tcheugui [23]USAProspective cohort144291 (2236/2055)Participants from Framingham Offspring StudyMean age: 44.7Obesity was defined based on the BMI. Metabolic health was defined according to the NCEP ATP III criteriaGFR < 60 or microalbuminuriaAge, sex, smoke6Nam [24]KoreaProspective cohort9.58589 (4479/4110)Participants from the KoGES51.9 ± 8.8Obesity was defined based on the BMI. Metabolic health was defined according to the ATP III criteriaGFR < 60Age, smoke, alcohol, physical activity, CVD, residence7Lin [25]ChinaProspective cohort3.92491 (1515/976)General population59.5 ± 9.1Obesity was defined based on the BMI. Metabolic health was defined according to the ATP III criteriaGFR < 60 or Albuminuria (UACR ≥ 30 mg/g)Sex, age, smoke, alcohol, GFR, physical activity, ALT, CRP, GGT, uric acid, HOMA-IR, CVD, education, occupation5Chang [26]KoreaProspective cohort1062,249 (30,812/31437)Participants from the Kangbuk Samsung Health Study36.1 ± 6.6Obesity was defined based on the BMI. Metabolic health was defined as a HOMA-IR < 2.5 and absence of any component of the metabolic syndromeGFR < 60Sex, age, smoke, alcohol, GFR, physical activity, ALT, CRP, GGT, LDL, HDL, TG, FBS, HOMA-IR, AST, SBP, study center, year of screening8Jung [27]KoreaProspective cohort3.241,194 (16,275/24919)Subjects who visited the Health Screening and Promotion Center of Asan Medical Center for routine medical examinations>20Obesity was defined based on the Asia–Pacific BMI criteria. Metabolic health was defined according to the ATP III criteriaGFR < 60Sex, age, smoke, alcohol, GFR, physical activity, CVD, ALT, uric acid, CRP, GGT, LDL8Mottaghi [28]IranProspective cohort8.15672 (3108/2564)Participants from the Tehran Lipid and Glucose Study40.4 ± 0.2Obesity was defined based on the BMI. Metabolic health was defined according to the NCEP ATP III criteriaStructural or functional abnormalities of kidney for at least 3 months, manifested by either kidney damage with or without GFR < 60 or a decreased GFR with or without other evidence of kidney damageSex, age, smoke, HTN, WC6Hashimoto [29]JapanRetrospective cohort83136 (1303/1833)Participants from the Oike Health SurveyAdult populationObesity was defined based on the BMI. Metabolic health was defined according to the IDF criteriaGFR < 60 or proteinuriaSex, age, smoke, alcohol, Cr, uric acid, SBP, HDL, IFG5Chen [30]ChinaCross-sectionalNA2324 (1568/756)General population≥18Obesity was defined based on the BMI. Metabolic health was defined according to the IDF criteriaGFR < 60 or albumin-to-creatinine ratio (ACR) ≥ 30Sex, age, smoke, alcohol, physical activity, education, traditional Chinese medicine, CRP5F female, M male, GFR glomerular filtration rate, IDF International Diabetes Federation, NA not applicable, SES socio-economic status, CVD cardiovascular disease, GGT γ-glutamyltransferase, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, NCEP ATP III National Cholesterol Education Program Adult Treatment Panel III, WC waist circumference, CRP C-reactive protein, FBS fasting blood sugar, HOMA-IR homeostasis model assessment of insulin resistance, SBP systolic blood pressure, IFG impaired fasting glucose, NOS Newcastle–Ottawa Scale, ACR albumin-to-creatinine ratio, KD kidney disease, Cr creatinine, HTN hypertension, LDL low-density lipoprotein Characteristics of the studies included in the meta-analysis F female, M male, GFR glomerular filtration rate, IDF International Diabetes Federation, NA not applicable, SES socio-economic status, CVD cardiovascular disease, GGT γ-glutamyltransferase, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, NCEP ATP III National Cholesterol Education Program Adult Treatment Panel III, WC waist circumference, CRP C-reactive protein, FBS fasting blood sugar, HOMA-IR homeostasis model assessment of insulin resistance, SBP systolic blood pressure, IFG impaired fasting glucose, NOS Newcastle–Ottawa Scale, ACR albumin-to-creatinine ratio, KD kidney disease, Cr creatinine, HTN hypertension, LDL low-density lipoprotein Statistical analysis All statistical analyses were performed using Stata, version 17.0 (Stata Crop, College Station, TX, USA). The effect size was pooled using the fixed method meta-analysis (inverse variance). If significant heterogeneity was present, the random-method (DerSimonian–Laird) was employed to pool effect sizes. The reference category was considered an MHNW group in all studies. The I2 index and Cochrane’s Q test were used to assess the heterogeneity between studies. The I2 interpretation is as follow: low if I2 < 30%, moderate if I2 = 30–75%, and high if I2 > 75%. Subgroup analyses were performed according to study design, and definition of kidney disease. Meta-regression was employed to investigate the potential confounding effects of variables, such as follow-up duration, age and sex on the association. Publication bias was investigated using Begg’s rank correlation and Egger’s linear regression. Results Search results Following a preliminary search using relevant keywords, we identified 4528 full-text articles. After eliminating duplicates and applying our inclusion and exclusion criteria through a two-phase review process (title and abstract review), we included 13 suitable observational studies (four cross-sectional and nine cohort studies) in our evaluation. Figure 1 provides an overview of the main study findings and details the procedure used for selecting relevant studies. This meta-analysis included 13 articles and 492,829 participants in total [18–30] (Table 1). Study characteristics The various features of the included studies are compiled in Table 1. The sample sizes varied from 2324 to 319,674 participants. Research was conducted in China [25, 30], Taiwan [21], Korea [20, 22, 24, 26, 27], Iran [18, 28], USA [19, 23], and Japan [29]. The follow-up period for cohort studies ranged from 3.2 to 14 years. BMI was employed in all trials to diagnose overweight and obesity. Both sexes were included in every study. Metabolic health was defined using the National Cholesterol Education Program’s Adult Treatment Panel (NCEP ATPIII) criteria [19–25, 27, 28] and the International Diabetes Federation (IDF) criteria [18, 29, 30]. One study [26] defined metabolic health as having a HOMA-IR < 2.5 and the absence of any metabolic syndrome components. The results of the included studies were adjusted for common confounders, including age, sex, physical activity, smoking status, alcohol use, socioeconomic factors, liver enzymes, inflammatory factors, lipid profile, and glucose profile. Comprehensive details on the studies included in the meta-analysis are provided in Table 1. Metabolically unhealthy normal-weight (MUNW) phenotype and KD risk We identified 12 relevant studies (encompassing 13 effect sizes) examining the relationship between the metabolically unhealthy normal weight (MUNW) phenotype and the risk of chronic kidney disease (CKD), totaling 430,580 participants. These studies reported various effect measures, such as odds ratios (OR) and hazard ratios (HR). Our systematic literature search yielded an overall effect estimate (OR/HR) of 1.58 with a corresponding 95% confidence interval (CI) of 1.43–1.76, regardless of the specific effect measure used. This indicates that individuals with the MUNW phenotype have a 58% higher risk of CKD compared to those with the metabolically healthy normal weight (MHNW) phenotype. A considerable variability was observed (I2 = 51.33%, P = 0.02). Detailed information can be found in Table 2 and Fig. 2. There was no evidence for small-study bias on the basis of the visual inspection of the funnel plot, Egger’s regression test, and Begg’s test in all studies together (Egger’s test P = 0.65; Begg’s test P = 0.42), studies reporting OR (Egger’s test P = 0.99; Begg’s test P = 1.00), and HR (Egger’s test P = 0.83; Begg’s test P = 1.00) for the observations concerning MUNW phenotype and KD risk.Table 2Overall and subgroup estimates of meta-analysis for the risk of kidney dysfunction among different phenotypes of obesity compared to metabolically healthy normal weight phenotypeObesity metabolic phenotypeOverall/subgroupsNo. of effect sizesReferencesES (95% CI)I2 (%)P heterogeneityP heterogeneity between subgroupsMUNWOverall13[18–29]1.58 (1.43–1.76)51.330.02–Type of effect measure0.55 Reporting OR7[18, 19, 21, 25, 28, 29]1.66 (1.35–2.03)57.550.02 Reporting HR6[20, 22–24, 26, 27]1.54 (1.35–1.75)51.330.06Study design0.75 Prospective cohort5[23–27]1.66 (1.34–2.06)55.630.06 Retrospective cohort3[20, 22, 28]1.51 (1.31–1.75)36.640.20 Cross-sectional5[18, 19, 21, 29]1.62 (1.26–2.07)67.780.01Definition of KD0.21 With proteinuria4[21, 23, 25, 28]1.82 (1.38–2.39)57.960.06 Without proteinuria9[18–20, 22, 24, 26, 27, 29]1.51 (1.36–1.68)42.240.08MHOWOverall3[1, 21, 27]1.34 (0.85–2.12)78.85<0.01–Type of effect measure0.58 Reporting OR2[1, 21]2.05 (0.38–10.95)87.99<0.01 Reporting HR1[27]1.27 (1.05–1.53)––MUOWOverall2[21, 27]1.63 (0.97–2.73)89.47<0.01–MHOOverall14[1, 18–29]1.20 (1.06–1.34)34.380.10–Type of effect measure0.14 Reporting OR8[1, 18, 19, 21, 25, 28, 29]1.05 (0.86–1.30)15.740.30 Reporting HR6[20, 22–24, 26, 27]1.26 (1.11–1.44)39.270.14Study design0.05 Prospective cohort6[1, 23–27]1.40 (1.13–1.75)36.600.16 Retrospective cohort3[20, 22, 28]1.21 (1.11–1.32)0.000.49 Cross-sectional5[18, 19, 21, 29]0.99 (0.82–1.20)0.000.47Definition of KD0.95 With proteinuria4[21, 23, 25, 28]1.19 (0.94–1.51)0.000.46 Without proteinuria10[1, 18–20, 22, 24, 26, 27, 29]1.20 (1.04–1.38)47.840.04MUOOverall13[18–29]1.90 (1.63–2.20)76.82<0.001–Type of effect measure0.53 Reporting OR7[18, 19, 21, 25, 28, 29]2.03 (1.51–2.72)76.93<0.001 Reporting HR6[20, 22–24, 26, 27]1.81 (1.50–2.20)80.49<0.001Study design0.97 Prospective cohort5[23–27]1.92 (1.42–2.60)77.85<0.01 Retrospective cohort3[20, 22, 28]1.84 (1.42–2.38)78.220.01 Cross-sectional5[18, 19, 21, 29]1.91 (1.33–2.76)83.11<0.001Definition of KD<0.01 With proteinuria4[21, 23, 25, 28]2.42 (2.06–2.85)0.000.72 Without proteinuria9[18–20, 22, 24, 26, 27, 29]1.73 (1.44–2.08)80.49<0.001ES effect size, MHNW metabolically healthy normal weight, MHOW metabolically healthy overweight, MUOW metabolically unhealthy overweight, MHO metabolically healthy obese, MUO metabolically unhealthy obese, KD kidney dysfunction, OR odds ratio, HR hazard ratioFig. 2Overall effect estimate of the association between metabolically unhealthy normal-weight (MUNW) phenotype and risk of kidney dysfunction Table 2Overall and subgroup estimates of meta-analysis for the risk of kidney dysfunction among different phenotypes of obesity compared to metabolically healthy normal weight phenotypeObesity metabolic phenotypeOverall/subgroupsNo. of effect sizesReferencesES (95% CI)I2 (%)P heterogeneityP heterogeneity between subgroupsMUNWOverall13[18–29]1.58 (1.43–1.76)51.330.02–Type of effect measure0.55 Reporting OR7[18, 19, 21, 25, 28, 29]1.66 (1.35–2.03)57.550.02 Reporting HR6[20, 22–24, 26, 27]1.54 (1.35–1.75)51.330.06Study design0.75 Prospective cohort5[23–27]1.66 (1.34–2.06)55.630.06 Retrospective cohort3[20, 22, 28]1.51 (1.31–1.75)36.640.20 Cross-sectional5[18, 19, 21, 29]1.62 (1.26–2.07)67.780.01Definition of KD0.21 With proteinuria4[21, 23, 25, 28]1.82 (1.38–2.39)57.960.06 Without proteinuria9[18–20, 22, 24, 26, 27, 29]1.51 (1.36–1.68)42.240.08MHOWOverall3[1, 21, 27]1.34 (0.85–2.12)78.85<0.01–Type of effect measure0.58 Reporting OR2[1, 21]2.05 (0.38–10.95)87.99<0.01 Reporting HR1[27]1.27 (1.05–1.53)––MUOWOverall2[21, 27]1.63 (0.97–2.73)89.47<0.01–MHOOverall14[1, 18–29]1.20 (1.06–1.34)34.380.10–Type of effect measure0.14 Reporting OR8[1, 18, 19, 21, 25, 28, 29]1.05 (0.86–1.30)15.740.30 Reporting HR6[20, 22–24, 26, 27]1.26 (1.11–1.44)39.270.14Study design0.05 Prospective cohort6[1, 23–27]1.40 (1.13–1.75)36.600.16 Retrospective cohort3[20, 22, 28]1.21 (1.11–1.32)0.000.49 Cross-sectional5[18, 19, 21, 29]0.99 (0.82–1.20)0.000.47Definition of KD0.95 With proteinuria4[21, 23, 25, 28]1.19 (0.94–1.51)0.000.46 Without proteinuria10[1, 18–20, 22, 24, 26, 27, 29]1.20 (1.04–1.38)47.840.04MUOOverall13[18–29]1.90 (1.63–2.20)76.82<0.001–Type of effect measure0.53 Reporting OR7[18, 19, 21, 25, 28, 29]2.03 (1.51–2.72)76.93<0.001 Reporting HR6[20, 22–24, 26, 27]1.81 (1.50–2.20)80.49<0.001Study design0.97 Prospective cohort5[23–27]1.92 (1.42–2.60)77.85<0.01 Retrospective cohort3[20, 22, 28]1.84 (1.42–2.38)78.220.01 Cross-sectional5[18, 19, 21, 29]1.91 (1.33–2.76)83.11<0.001Definition of KD<0.01 With proteinuria4[21, 23, 25, 28]2.42 (2.06–2.85)0.000.72 Without proteinuria9[18–20, 22, 24, 26, 27, 29]1.73 (1.44–2.08)80.49<0.001ES effect size, MHNW metabolically healthy normal weight, MHOW metabolically healthy overweight, MUOW metabolically unhealthy overweight, MHO metabolically healthy obese, MUO metabolically unhealthy obese, KD kidney dysfunction, OR odds ratio, HR hazard ratio Overall and subgroup estimates of meta-analysis for the risk of kidney dysfunction among different phenotypes of obesity compared to metabolically healthy normal weight phenotype ES effect size, MHNW metabolically healthy normal weight, MHOW metabolically healthy overweight, MUOW metabolically unhealthy overweight, MHO metabolically healthy obese, MUO metabolically unhealthy obese, KD kidney dysfunction, OR odds ratio, HR hazard ratio Overall effect estimate of the association between metabolically unhealthy normal-weight (MUNW) phenotype and risk of kidney dysfunction We employed a stratified strategy, recognizing the distinct characteristics of these effect measures and their potential influence on interpreting associations. To enhance the precision of our findings, we pooled studies separately based on the type of effect measure. In subsequent analyses, we distinguished between studies reporting odds ratios (OR) and those reporting hazard ratios (HR) to address variations in research design and methodology. The pooled analysis of studies reporting ORs demonstrated a strong positive correlation between the MUNW phenotype and the risk of kidney disease (KD), with a combined effect estimate of 1.66 and a 95% confidence interval (CI) of 1.35–2.03 (Table 2). This finding substantiates that individuals with the MUNW phenotype have a 66% higher risk of KD compared to those with the metabolically healthy normal weight (MHNW) phenotype. On the other hand, in the subgroup of studies reporting HR, the overall effect estimate (HR) was 1.54 with a 95%CI (1.35–1.75) (Table 2). Additional subgroup analyses based on research design and the definition of KD further substantiated the significant relationship between the metabolically unhealthy normal weight (MUNW) phenotype and the development of KD within each subgroup (Table 2). These analyses consistently indicated a substantial association between MUNW and increased KD risk, underscoring the robustness of the observed link across various study designs and KD definitions. Metabolically healthy overweight and metabolically unhealthy overweight phenotypes and KD risk Three prospective cohort studies [21, 26, 28], encompassing a total of 82,904 participants, investigated the relationship between the metabolically healthy overweight (MHOW) phenotype and the risk of KD. Additionally, two studies [21, 28] involving 20,655 participants examined the risk associated with the metabolically unhealthy overweight (MUHOW) phenotype. Individuals with the MHOW phenotype exhibited a non-significant higher risk of KD events compared to those with the metabolically healthy normal weight (MHNW) phenotype, with an effect size (ES) of 1.34 (95% CI = 0.85–2.12) (Table 2; Fig. 3). There was considerable between-study heterogeneity (I2 = 78.85%, P < 0.01). Visual inspection of the funnel plot and results from Begg’s test indicated no signs of publication bias (Begg’s test P = 1.00).Fig. 3Overall effect estimate of the association between metabolically healthy overweight (MHOW) phenotype and risk of kidney dysfunction Overall effect estimate of the association between metabolically healthy overweight (MHOW) phenotype and risk of kidney dysfunction When comparing the risk of KD among MHOW against MHNW phenotype, Egger’s test revealed a substantial publication bias (Egger’s test P = 0.03). Moreover, Table 2 indicates that there was no significant connection between MUOW persons and the risk of CKD (ES = 1.63, 95% CI = 0.97–2.73), evidence of considerable heterogeneity (I2 = 89.47%, P < 0.01), and no indication of publication bias (Egger’s test P = 0.33) when compared to the MHNW phenotype. Metabolically healthy obese and metabolically unhealthy obese phenotypes and KD risk The study of KD risk in connection to MHO phenotype comprised a total of 13 observational studies [18–30] with 492,829 individuals. These studies provided a variety of effect measures, such as odds ratios (OR) and hazard ratios (HR). Furthermore, 12 studies with 430,580 people examined the relationship between the MUHO phenotype and incident KD risk. Upon aggregating all studies, irrespective of the impact measure utilized, the findings indicated that the MHO phenotype was linked to a 20.0% higher risk of CKD in contrast to the MHNW phenotype (ES = 1.20, 95% CI = 1.06–1.34) (Table 2; Fig. 4).Fig. 4Overall effect estimate of the association between metabolically healthy obese (MHO) phenotype and risk of kidney dysfunction Overall effect estimate of the association between metabolically healthy obese (MHO) phenotype and risk of kidney dysfunction The effect sizes for these associations did not show any significant evidence of heterogeneity between studies (I2 = 34.38%, P = 0.10), and no evidence of bias was found in the combined studies (Egger’s test P = 0.67; Begg’s test P = 0.58), in the studies that reported OR (Egger’s test P = 0.98; Begg’s test P = 0.71), or in the studies that reported HR (Egger’s test P = 0.58; Begg’s test P = 0.70). Comparatively, the MUO participants’ comparable pooled ES was 1.90 (95% CI = 1.63–2.20) (Table 2; Fig. 5). When the degree of the connection was assessed, there was, however, considerable variability in the individual estimates (I2 = 76.82%, P < 0.001), and there was no indication of publication bias across all studies combined (Egger’s test P = 0.31; Begg’s test P = 0.95), studies reporting OR (Egger’s test P = 0.42; Begg’s test P = 1.00), HR (Egger’s test P = 0.91; Begg’s test P = 1.00).Fig. 5Overall effect estimate of the association between metabolically unhealthy obese (MUO) phenotype and risk of kidney dysfunction Overall effect estimate of the association between metabolically unhealthy obese (MUO) phenotype and risk of kidney dysfunction A substantial positive association between the MUNW phenotype and KD risk was found in the pooled analysis of studies reporting odds ratios (OR), with the combined effect estimate showing an effect size (ES) of 1.05 (95% CI = 0.86–1.30) for the MUNW phenotype. Additionally, for the metabolically healthy obese (MHO) and metabolically unhealthy obese (MUO) phenotypes, the ES was 2.03 (95% CI = 1.51–2.72) and 1.26 (95% CI = 1.11–1.44) for MHO, and 1.81 (95% CI = 1.50–2.20) for MUO, respectively (Table 2). The subset of studies reporting hazard ratios (HR) indicated an overall effect estimate (HR) for MHO and MUO as 1.26 (95% CI = 1.11–1.44) and 1.81 (95% CI = 1.50–2.20), respectively (Table 2). No indication of publication bias was found according to Egger’s test (for MHO, P = 0.58; for MUO, P = 0.91) and Begg’s test (for MHO, P = 0.70; for MUO, P = 1.00). Subgroup analysis The pooled analysis of metabolic obesity phenotypes and the development of kidney disease (KD) for studies reporting odds ratios (OR) and hazard ratios (HR) revealed significant statistical heterogeneity. Consequently, subgroup analyses were conducted to better understand these relationships. Subgroup analyses of studies reporting OR indicated a significant relationship between the MUNW phenotype and KD development. This relationship was observed in the cross-sectional subgroup and both subgroups defined by different KD criteria (Table 3). However, no significant relationship was found in other subgroups (Table 3).Table 3Subgroup estimates of studies reporting OR for the risk of kidney dysfunction among different phenotypes of obesity compared to metabolically healthy normal weight phenotypeObesity metabolic phenotypeSubgroupsNo. of effect sizesOR (95% CI)I2 (%)P heterogeneityP heterogeneity between subgroupsMUNWStudy design0.48 Prospective cohort12.14 (1.36–3.37)–– Retrospective cohort11.44 (0.80–2.58)–– Cross-sectional51.62 (2.26–2.07)67.780.01Definition of KD<0.01 With proteinuria32.13 (1.73–2.61)0.990.36 Without proteinuria41.39 (1.20–1.61)0.000.76MHOStudy design0.32 Prospective cohort21.71 (0.82–3.57)10.770.29 Retrospective cohort10.83 (0.38–1.81)–– Cross-sectional50.99 (0.82–1.20)0.000.47Definition of KD0.07 With proteinuria31.27 (0.96–1.67)0.000.46 Without proteinuria50.93 (0.75–1.15)0.000.44MUOStudy design0.60 Prospective cohort12.20 (1.44–3.37)–– Retrospective cohort12.80 (1.46–5.38)–– Cross-sectional51.92 (1.33–2.77)83.11<0.001Definition of KD0.05 With proteinuria32.55 (2.09–3.10)0.000.74 Without proteinuria41.72 (1.23–2.41)66.330.03ES effect size, MHNW metabolically healthy normal weight, MHO metabolically healthy obese, MUO metabolically unhealthy obese, KD kidney dysfunction, OR odds ratio Table 3Subgroup estimates of studies reporting OR for the risk of kidney dysfunction among different phenotypes of obesity compared to metabolically healthy normal weight phenotypeObesity metabolic phenotypeSubgroupsNo. of effect sizesOR (95% CI)I2 (%)P heterogeneityP heterogeneity between subgroupsMUNWStudy design0.48 Prospective cohort12.14 (1.36–3.37)–– Retrospective cohort11.44 (0.80–2.58)–– Cross-sectional51.62 (2.26–2.07)67.780.01Definition of KD<0.01 With proteinuria32.13 (1.73–2.61)0.990.36 Without proteinuria41.39 (1.20–1.61)0.000.76MHOStudy design0.32 Prospective cohort21.71 (0.82–3.57)10.770.29 Retrospective cohort10.83 (0.38–1.81)–– Cross-sectional50.99 (0.82–1.20)0.000.47Definition of KD0.07 With proteinuria31.27 (0.96–1.67)0.000.46 Without proteinuria50.93 (0.75–1.15)0.000.44MUOStudy design0.60 Prospective cohort12.20 (1.44–3.37)–– Retrospective cohort12.80 (1.46–5.38)–– Cross-sectional51.92 (1.33–2.77)83.11<0.001Definition of KD0.05 With proteinuria32.55 (2.09–3.10)0.000.74 Without proteinuria41.72 (1.23–2.41)66.330.03ES effect size, MHNW metabolically healthy normal weight, MHO metabolically healthy obese, MUO metabolically unhealthy obese, KD kidney dysfunction, OR odds ratio Subgroup estimates of studies reporting OR for the risk of kidney dysfunction among different phenotypes of obesity compared to metabolically healthy normal weight phenotype ES effect size, MHNW metabolically healthy normal weight, MHO metabolically healthy obese, MUO metabolically unhealthy obese, KD kidney dysfunction, OR odds ratio For studies reporting HR, subgroup analyses revealed a significant relationship between MUNW and KD development within each subgroup, divided by study design and KD definition (Table 4). These findings suggest that the association between MUNW and KD is robust across various study designs and definitions of KD. Subgroup analyses of studies reporting OR found no significant association between the MHO phenotype and the development of KD (Table 3). However, subgroup analyses of studies reporting HR revealed a significant correlation between the MHO phenotype and KD development within each subgroup, classified by study design and KD definition (Table 4). These findings highlight the importance of considering study design and KD definitions when assessing the relationship between MHO and KD. In subgroup analyses of studies reporting HR, a significant association between the MUO phenotype and the development of kidney disease (KD) was evident within each subgroup categorized by study design, particularly when proteinuria was not included in the definition of KD (Table 4). Similarly, subgroup analyses of studies reporting OR indicated a significant association between the MUO phenotype and KD development. This was observed in the cross-sectional subgroup and both subgroups defined by different KD criteria (Table 3). These results suggest a robust relationship between the MUO phenotype and increased risk of KD across various study designs and definitions.Table 4Subgroup estimates of studies reporting HR for the risk of kidney dysfunction among different phenotypes of obesity compared to metabolically healthy normal weight phenotypeObesity metabolic phenotypeSubgroupsNo of effect sizesHR (95%CI)I2 (%)P heterogeneityP heterogeneity between subgroupsMUNWStudy design0.68 Prospective cohort41.59 (1.26–2.02)59.440.06 Retrospective cohort21.49 (1.23–1.81)67.230.08Definition of KD0.62 With proteinuria11.44 (1.10–1.89)–– Without proteinuria51.56 (1.33–1.82)59.870.04MHOStudy design0.39 Prospective cohort41.37 (1.05–1.77)52.850.09 Retrospective cohort21.21 (1.11–1.32)0.000.47Definition of KD0.27 With proteinuria10.97 (0.60–1.57)–– Without proteinuria51.29 (1.12–1.48)44.490.12MUOStudy design0.75 Prospective cohort41.87 (1.31–2.69)82.86<0.01 Retrospective cohort21.74 (1.32–2.30)87.37<0.01Definition of KD0.23 With proteinuria12.19 (1.65–2.90)–– Without proteinuria51.75 (1.40–2.20)83.81<0.001ES effect size, MHNW metabolically healthy normal weight, MHO metabolically healthy obese, MUO metabolically unhealthy obese, KD kidney dysfunction, HR hazard ratio Table 4Subgroup estimates of studies reporting HR for the risk of kidney dysfunction among different phenotypes of obesity compared to metabolically healthy normal weight phenotypeObesity metabolic phenotypeSubgroupsNo of effect sizesHR (95%CI)I2 (%)P heterogeneityP heterogeneity between subgroupsMUNWStudy design0.68 Prospective cohort41.59 (1.26–2.02)59.440.06 Retrospective cohort21.49 (1.23–1.81)67.230.08Definition of KD0.62 With proteinuria11.44 (1.10–1.89)–– Without proteinuria51.56 (1.33–1.82)59.870.04MHOStudy design0.39 Prospective cohort41.37 (1.05–1.77)52.850.09 Retrospective cohort21.21 (1.11–1.32)0.000.47Definition of KD0.27 With proteinuria10.97 (0.60–1.57)–– Without proteinuria51.29 (1.12–1.48)44.490.12MUOStudy design0.75 Prospective cohort41.87 (1.31–2.69)82.86<0.01 Retrospective cohort21.74 (1.32–2.30)87.37<0.01Definition of KD0.23 With proteinuria12.19 (1.65–2.90)–– Without proteinuria51.75 (1.40–2.20)83.81<0.001ES effect size, MHNW metabolically healthy normal weight, MHO metabolically healthy obese, MUO metabolically unhealthy obese, KD kidney dysfunction, HR hazard ratio Subgroup estimates of studies reporting HR for the risk of kidney dysfunction among different phenotypes of obesity compared to metabolically healthy normal weight phenotype ES effect size, MHNW metabolically healthy normal weight, MHO metabolically healthy obese, MUO metabolically unhealthy obese, KD kidney dysfunction, HR hazard ratio Meta-regression Meta-regression analysis revealed that age significantly influenced the association between the MUNW phenotype and the risk of KD (Table 5). This effect was significant only in studies reporting odds ratios (OR) (coefficient = 0.051, SE = 0.015, P value <0.01).Table 5Meta-regression for the effect of age, follow-up duration, and sexObesity metabolic phenotypeType of effect measurePotential confounderNo. of effect sizeCoefficientSEP valueI2MUNW vs. MHNWStudies reporting OR/HRAge130.0230.0130.0745.25Follow-up duration8−0.0110.0150.4443.07Female percent13−0.0010.0020.6151.99Studies reporting ORAge70.0510.015<0.010.00Female percent7−0.0020.0030.5151.02Studies reporting HRAge60.0090.0190.6056.52Follow-up duration6−0.0070.0170.6955.51Female percent60.0200.0110.0734.72MHOW vs. MHNWStudies reporting OR/HRAge3−0.1080.1130.3481.98Follow-up duration20.7510.7560.32100.00Female percent3−0.0100.0480.8287.64MHO vs. MHNWStudies reporting OR/HRAge140.0120.0110.2834.59Follow-up duration9−0.0120.0170.4536.18Female percent14−0.0020.0020.3131.85Studies reporting ORAge80.0310.0200.120.00Follow-up duration30.0740.2620.7762.51Female percent8−0.0020.0030.5318.44Studies reporting HRAge60.0030.0140.8151.42Follow-up duration6−0.0110.0180.5249.04Female percent6−0.0010.0040.9251.38MUO vs. MHNWStudies reporting OR/HRAge130.0220.0180.2374.33Follow-up duration8−0.0010.0240.9975.95Female percent13−0.0050.0020.0367.27Studies reporting ORAge70.0160.0340.6375.11Follow-up duration20.0580.0990.55100.00Female percent7−0.0080.001<0.0010.00Studies reporting HRAge60.0220.0250.3679.90Follow-up duration60.0010.0070.9884.34Female percent60.0050.0280.8382.72SE standard error, MHNW metabolically healthy normal weight, MHOW metabolically healthy overweight, MUOW metabolically unhealthy overweight, MHO metabolically healthy obese, MUO metabolically unhealthy obese Table 5Meta-regression for the effect of age, follow-up duration, and sexObesity metabolic phenotypeType of effect measurePotential confounderNo. of effect sizeCoefficientSEP valueI2MUNW vs. MHNWStudies reporting OR/HRAge130.0230.0130.0745.25Follow-up duration8−0.0110.0150.4443.07Female percent13−0.0010.0020.6151.99Studies reporting ORAge70.0510.015<0.010.00Female percent7−0.0020.0030.5151.02Studies reporting HRAge60.0090.0190.6056.52Follow-up duration6−0.0070.0170.6955.51Female percent60.0200.0110.0734.72MHOW vs. MHNWStudies reporting OR/HRAge3−0.1080.1130.3481.98Follow-up duration20.7510.7560.32100.00Female percent3−0.0100.0480.8287.64MHO vs. MHNWStudies reporting OR/HRAge140.0120.0110.2834.59Follow-up duration9−0.0120.0170.4536.18Female percent14−0.0020.0020.3131.85Studies reporting ORAge80.0310.0200.120.00Follow-up duration30.0740.2620.7762.51Female percent8−0.0020.0030.5318.44Studies reporting HRAge60.0030.0140.8151.42Follow-up duration6−0.0110.0180.5249.04Female percent6−0.0010.0040.9251.38MUO vs. MHNWStudies reporting OR/HRAge130.0220.0180.2374.33Follow-up duration8−0.0010.0240.9975.95Female percent13−0.0050.0020.0367.27Studies reporting ORAge70.0160.0340.6375.11Follow-up duration20.0580.0990.55100.00Female percent7−0.0080.001<0.0010.00Studies reporting HRAge60.0220.0250.3679.90Follow-up duration60.0010.0070.9884.34Female percent60.0050.0280.8382.72SE standard error, MHNW metabolically healthy normal weight, MHOW metabolically healthy overweight, MUOW metabolically unhealthy overweight, MHO metabolically healthy obese, MUO metabolically unhealthy obese Meta-regression for the effect of age, follow-up duration, and sex SE standard error, MHNW metabolically healthy normal weight, MHOW metabolically healthy overweight, MUOW metabolically unhealthy overweight, MHO metabolically healthy obese, MUO metabolically unhealthy obese Furthermore, the risk of incident KD in the comparison of MUO versus MHNW was significantly modified by sex in the overall analysis of OR/HR and specifically in studies reporting OR. However, in other instances, meta-regression did not detect any significant link between obesity phenotypes and incident KD in relation to age, follow-up duration, and percentage of female participants. These findings highlight the importance of considering demographic factors such as age and sex when evaluating the risk of KD associated with different obesity phenotypes. Discussion We examined the combined impact of BMI and metabolic health status on the risk of CKD in the current meta-analysis of 13 observational studies involving 492,829 participants. The findings showed that, in contrast to MHNW subjects, overweight and obese individuals had a significantly higher risk for CKD even in the absence of overt metabolic abnormalities. Furthermore, this meta-analysis demonstrated that overweight and obese individuals are at higher risk for CKD regardless of their metabolic status, refuting the idea that being overweight and obese without metabolic abnormalities is a benign condition. Various prospective longitudinal studies reported inconsistent effects of obesity-metabolic subphenotypes on the risk of CKD [31–33]. A meta-analysis of nine prospective cohort studies [34] indicated that individuals with metabolic abnormalities are more likely to develop CKD even if they maintain a normal weight. Obese and overweight individuals who are otherwise healthy were also found to be at increased risk of CKD. Another meta-analysis found that a higher body mass index (BMI) is associated with a progressively greater risk of renal disease progression [35]. Additionally, research examining the relationship between renal disease and metabolic syndrome [36] showed that the risk increases proportionally with the number of metabolic syndrome components present. Specifically, the odds ratios (ORs) for CKD increased from 1.39 to 1.96 as the number of components increased from two to five, with rising increments of 0.03, 0.24, and 0.3. The inconsistent outcomes observed across various studies may be attributed to different classifications of CKD, as many studies did not include proteinuria and kidney structural abnormalities as markers. None of the aforementioned studies applied structural changes in the kidney when defining CKD, and this might have resulted in them missing the early stage of CKD. Another explanation may be related to the different metabolic status of the obesity phenotypes and the lack of consensus for the definition of MHO [21]. Independent of metabolic risk factors, several common biological states link obesity to kidney dysfunction. These include hemodynamic changes, oxidative stress, hormonal effects, and activation of the renin–angiotensin–aldosterone system [37–39]. Adipose tissue acts as an active endocrine organ, and dysregulation in the production of adipokines and cytokines derived from adipose tissue, such as leptin, adiponectin, tumor necrosis factor-α, interleukin-6, and plasminogen activator inhibitor-1, may also contribute to the pathogenesis of chronic kidney disease (CKD) in overweight and obese individuals [39–41]. Low mitochondrial number and activity in adipose tissue have been suggested as underlying factors in metabolic syndrome (MetS). Recent studies have shown that mitochondrial dysfunction is involved in obesity-related metabolic diseases, evidenced by the downregulation of mitochondrial biogenesis, oxidative metabolic pathways, and oxidative phosphorylation (OXPHOS) proteins [42]. These findings indicate that impaired mitochondrial biogenesis in adipocytes is a potential mechanism contributing to energy imbalance and metabolic homeostasis disturbances in MetS. It is unclear what processes determine a person’s metabolic state when they have the same body mass index. The primary issue put forth is the distribution pattern of fat, with excess visceral fat having a greater negative impact on metabolic health than excess subcutaneous fat [43]. Furthermore, recent research indicates that behavioral and contextual variables [46], genetic and epigenetic programming [44, 45], and ethnicity may also be relevant factors. Individuals with a MUNW phenotype exhibit metabolic problems despite having a normal BMI. These disturbances are characterized by low levels of physical activity, low lean body mass, low resting metabolic rate, low insulin sensitivity, and a high body fat percentage, especially visceral fat [47]. The primary strength of this study lies in its relatively large pooled sample size, which enables robust estimates of the relationship between the six BMI–metabolic categories and related diseases, providing precision that individual studies might lack. Additionally, the inclusion and separate analysis of both prospective cohort studies and cross-sectional studies in this meta-analysis offer a comprehensive understanding of the association between obese-metabolic subphenotypes and chronic kidney disease (CKD) risk. Given the association between the MUNW phenotype and increased risk of CKD and other diseases [48, 49], early identification of MUNW individuals is crucial. These individuals often elude screening because they are not perceived as high risk, yet early detection is important for predicting and preventing renal insufficiency. However, several limitations of our study should be acknowledged. First, the period of exposure to the present metabolic phenotype and longitudinal changes in metabolic status and BMI were not recorded in the research, which might partially alter the predicted risk. Research has indicated that metabolic wellness in obese individuals may be a temporary state that is becoming more prevalent [49]. Therefore, it is more probable that changes in weight and metabolism will have a greater influence on CKD risk than cross-sectional weight status. Second, none of the included studies provided information on the relative changes in GFR and proteinuria across the follow-up periods. Third, there was a noticeable amount of variability in the analysis between the various phenotypic categories. Another key limitation of our study is the inability to differentiate between individuals with and without diabetes mellitus and arterial hypertension in the included studies. The metabolic health definitions based on the NCEP ATPIII and IDF criteria encompass both groups, preventing us from performing subgroup analyses by diabetes and hypertension status. This limitation may affect our interpretation of the relationship between metabolic health and kidney disease outcomes. Future research should explicitly account for both diabetes and hypertension status to better understand their independent impacts on metabolic health and kidney health. Conclusion All metabolically abnormal individuals are at a higher risk for chronic kidney disease (CKD) compared with corresponding healthy individuals, and our current meta-analysis of observational studies supports the idea of heterogeneity in metabolic status among individuals within similar BMI categories. Therefore, assessing both BMI and metabolic status simultaneously is crucial for estimating CKD risk in high-risk populations. Furthermore, effective measures should be implemented to prevent and control obesity and metabolic abnormalities. With the exception of MUOW individuals, significantly elevated risks for incident and prevalent CKD were observed in other obesity-metabolic groups. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 25 KB) Supplementary file1 (DOCX 25 KB)